Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer

A promising molecular target for aggressive cancers is the urokinase receptor (uPAR). A fully human, recombinant antibody that binds uPAR to form a stable complex that blocks uPA-uPAR interactions (2G10) and is internalized primarily through endocytosis showed efficacy in a mouse xenograft model of highly aggressive, triple negative breast cancer (TNBC). Antibody-drug conjugates (ADCs) of 2G10 were designed and produced bearing tubulin inhibitor payloads ligated through seven different linkers. Aldehyde tag technology was employed for linking, and either one or two tags were inserted into the antibody heavy chain, to produce site-specifically conjugated ADCs with drug-to-antibody ratios of either two or four. Both cleavable and non-cleavable linkers were combined with two different antimitotic toxins—MMAE (monomethylauristatin E) and maytansine. Nine different 2G10 ADCs were produced and tested for their ability to target uPAR in cell-based assays and a mouse model. The anti-uPAR ADC that resulted in tumor regression comprised an MMAE payload with a cathepsin B cleavable linker, 2G10-RED-244-MMAE. This work demonstrates in vitro activity of the 2G10-RED-244-MMAE in TNBC cell lines and validates uPAR as a therapeutic target for TNBC.

[1]  W. Gerwick,et al.  Exploration of the carmaphycins as payloads in antibody drug conjugate anticancer agents. , 2019, European journal of medicinal chemistry.

[2]  L. Mecklenburg.  A Brief Introduction to Antibody–Drug Conjugates for Toxicologic Pathologists , 2018, Toxicologic pathology.

[3]  David Rabuka,et al.  Leveraging Formylglycine-Generating Enzyme for Production of Site-Specifically Modified Bioconjugates. , 2018, Methods in molecular biology.

[4]  M. Sliwkowski,et al.  Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates. , 2017, Cancer research.

[5]  P. Drake,et al.  Recent Developments in ADC Technology: Preclinical Studies Signal Future Clinical Trends , 2017, BioDrugs.

[6]  A. Jacinto,et al.  How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment , 2017, ESMO Open.

[7]  S. Cianférani,et al.  Insights from native mass spectrometry approaches for top- and middle- level characterization of site-specific antibody-drug conjugates , 2017, mAbs.

[8]  J. Lambert,et al.  Antibody–Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review , 2017, Advances in Therapy.

[9]  C. Dumontet,et al.  Strategies and challenges for the next generation of antibody–drug conjugates , 2017, Nature Reviews Drug Discovery.

[10]  David J. Fleet,et al.  cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination , 2017, Nature Methods.

[11]  P. Drake,et al.  A simple LC/MRM-MS-based method to quantify free linker-payload in antibody-drug conjugate preparations. , 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[12]  E. Lindahl,et al.  Accelerated cryo-EM structure determination with parallelisation using GPUs in RELION-2 , 2016, bioRxiv.

[13]  D. Goldenberg,et al.  Prospects and progress of antibody-drug conjugates in solid tumor therapies , 2016, Expert opinion on biological therapy.

[14]  F. Loganzo,et al.  Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect? , 2016, Biochemical pharmacology.

[15]  Taleen Jerjian,et al.  Antibody‐Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy , 2016, Pharmacotherapy.

[16]  C. Anders,et al.  The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics. , 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[17]  P. Drake,et al.  An emerging playbook for antibody-drug conjugates: lessons from the laboratory and clinic suggest a strategy for improving efficacy and safety. , 2015, Current opinion in chemical biology.

[18]  Kai Zhang,et al.  Gctf: Real-time CTF determination and correction , 2015, bioRxiv.

[19]  Edmund A. Rossi,et al.  Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) , 2015, Oncotarget.

[20]  H. El-Hadaad,et al.  Current approaches in treatment of triple-negative breast cancer , 2015, Cancer biology & medicine.

[21]  P. Drake,et al.  Generating site-specifically modified proteins via a versatile and stable nucleophilic carbon ligation. , 2015, Chemistry & biology.

[22]  R. Stroud,et al.  Subnanometre-resolution electron cryomicroscopy structure of a heterodimeric ABC exporter , 2014, Nature.

[23]  R. Ubink,et al.  The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers , 2015, Molecular Cancer Therapeutics.

[24]  P. Drake,et al.  Exploring the effects of linker composition on site-specifically modified antibody-drug conjugates. , 2014, European journal of medicinal chemistry.

[25]  Zev J. Gartner,et al.  A Modular Approach for Assembling Aldehyde-Tagged Proteins on DNA Scaffolds , 2014, Journal of the American Chemical Society.

[26]  P. Drake,et al.  Aldehyde Tag Coupled with HIPS Chemistry Enables the Production of ADCs Conjugated Site-Specifically to Different Antibody Regions with Distinct in Vivo Efficacy and PK Outcomes , 2014, Bioconjugate chemistry.

[27]  C. Craik,et al.  Imaging the Urokinase Plasminongen Activator Receptor in Preclinical Breast Cancer Models of Acquired Drug Resistance , 2014, Theranostics.

[28]  Derek S. Chan,et al.  Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer , 2013, Proceedings of the National Academy of Sciences.

[29]  P. Drake,et al.  Hydrazino-Pictet-Spengler ligation as a biocompatible method for the generation of stable protein conjugates. , 2013, Bioconjugate chemistry.

[30]  R. Abraham,et al.  The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics. , 2013, Natural product reports.

[31]  J. Gray,et al.  Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer. , 2013, Cancer research.

[32]  P. Carter,et al.  Antibody-drug conjugates in cancer therapy. , 2013, Annual review of medicine.

[33]  T. Gress,et al.  Improving drug delivery to pancreatic cancer: breaching the stromal fortress by targeting hyaluronic acid , 2012, Gut.

[34]  C. Bertozzi,et al.  Site-specific chemical protein conjugation using genetically encoded aldehyde tags , 2012, Nature Protocols.

[35]  K. Juhl,et al.  Quantitative PET of Human Urokinase-Type Plasminogen Activator Receptor with 64Cu-DOTA-AE105: Implications for Visualizing Cancer Invasion , 2012, The Journal of Nuclear Medicine.

[36]  David S. Booth,et al.  Visualizing proteins and macromolecular complexes by negative stain EM: from grid preparation to image acquisition. , 2011, Journal of visualized experiments : JoVE.

[37]  V. Kadambi,et al.  Antibody drug conjugates - Trojan horses in the war on cancer. , 2011, Journal of pharmacological and toxicological methods.

[38]  K. Friedrich,et al.  Prognostic relevance of tumour cell‐associated uPAR expression in invasive ductal breast carcinoma , 2010, Histopathology.

[39]  C. Craik,et al.  Antagonistic Anti-urokinase Plasminogen Activator Receptor (uPAR) Antibodies Significantly Inhibit uPAR-mediated Cellular Signaling and Migration* , 2010, The Journal of Biological Chemistry.

[40]  F. Blasi,et al.  The urokinase receptor: Focused cell surface proteolysis, cell adhesion and signaling , 2010, FEBS letters.

[41]  D. Benjamin,et al.  Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate , 2010, Clinical Cancer Research.

[42]  H. Allgayer,et al.  Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact. , 2009, Histology and histopathology.

[43]  R. Hildenbrand,et al.  The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion. , 2009, International journal of oncology.

[44]  K. Cortese,et al.  Clathrin and LRP-1-Independent Constitutive Endocytosis and Recycling of uPAR , 2008, PloS one.

[45]  Aamir Ahmad,et al.  Evolving role of uPA/uPAR system in human cancers. , 2008, Cancer treatment reviews.

[46]  F. Blasi,et al.  The urokinase plasminogen activator system in cancer: Recent advances and implication for prognosis and therapy , 2003, Cancer and Metastasis Reviews.

[47]  P. Choong,et al.  Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases — A comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases , 2000, Breast Cancer Research and Treatment.

[48]  M. Duffy.  Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers. , 2001, Biochemical Society transactions.

[49]  B. Nielsen,et al.  The Murine Receptor for Urokinase-Type Plasminogen Activator Is Primarily Expressed in Tissues Actively Undergoing Remodeling , 2001, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[50]  E. Dublin,et al.  Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology. , 2000, The American journal of pathology.

[51]  Y. Miyagi,et al.  A Role for Tissue Factor in Cell Adhesion and Migration Mediated by Interaction with Actin-binding Protein 280 , 1998, The Journal of cell biology.

[52]  P. Carmeliet,et al.  Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[53]  S. Mandriota,et al.  Vascular Endothelial Growth Factor Increases Urokinase Receptor Expression in Vascular Endothelial Cells (*) , 1995, The Journal of Biological Chemistry.

[54]  M. Gyetko,et al.  The urokinase receptor is required for human monocyte chemotaxis in vitro. , 1994, The Journal of clinical investigation.

[55]  B. Ljung,et al.  The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. , 1994, Cancer research.